We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Biotech Growth Trust plc (The) (BIOG) Ordinary 25p

Sell:896.00p Buy:902.00p 0 Change: 27.00p (2.94%)
Market closed Prices as at close on 28 January 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:896.00p
Buy:902.00p
Change: 27.00p (2.94%)
Market closed Prices as at close on 28 January 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:896.00p
Buy:902.00p
Change: 27.00p (2.94%)
Market closed Prices as at close on 28 January 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Objective

The Company seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis.
Security Weight
Horizon Therapeutics plc Ordinary Shares 4.95%
Neurocrine Biosciences Inc 3.86%
Guardant Health Inc 3.76%
SICHUAN - PFD 3.53%
GH Research PLC 3.51%
Vertex Pharmaceuticals Inc 3.26%
Yisheng 3.10%
Gilead Sciences Inc 2.70%
Immunogen Inc 2.64%
Biogen Inc 2.56%
Sector Weight
Healthcare 95.00%
Country Weight
United States 72.38%
China 7.56%
Canada 3.94%
Ireland 3.51%
United Kingdom 2.51%
Switzerland 2.42%
South Korea 0.73%
France 0.72%
Singapore 0.47%
Germany 0.37%

Fee Structure

AIFM receives a periodic fee equal to 0.30% p.a. of the market capitalisation up to GBP500m, 0.20% above GBP 500m to GBP 1bn and 0.10% over GBP 1bn. The Investment Manager receives a fee equal to 0.65% p.a. of the net assets. The Agreement may be terminated with not less than 12 months notice.

Dividend Policy

The Company invests with the objective of achieving capital growth and it is expected that dividends, if any, are likely to be small. The Board intends only to pay dividends on the Company shares to the extent required in order to maintain the Company investment trust status.

ASSET SPLIT

Total number of holdings: 84.

Trust Manager

Geoffrey Hsu

Manager Bio

Hsu joined OrbiMed in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. Hsu has earned the right to use the Chartered Financial Analyst designation.

Board Of Directors

Andrew JoyChairman, Geoffrey Hsu, Steven Bates, Roger Yates, Julia Le Blan, David Willetts, Nicola Shepherd

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.